|

JIN-A02 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • J Ints Bio1

Indications

  • EGFR Mutant Advanced Non-Small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Orange, California1 trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.